{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:27:01Z","timestamp":1761514021649},"reference-count":32,"publisher":"Elsevier BV","issue":"31","license":[{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"UK Ministry of Defence"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1016\/j.vaccine.2017.05.058","type":"journal-article","created":{"date-parts":[[2017,6,10]],"date-time":"2017-06-10T19:01:52Z","timestamp":1497121312000},"page":"3889-3896","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Comparative Efficacy of Intramuscular and Scarification Routes of Administration of Live Smallpox Vaccine in a Murine Challenge Model"],"prefix":"10.1016","volume":"35","author":[{"given":"A.","family":"Phelps","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.J.","family":"Gates","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Eastaugh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Hillier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.O.","family":"Ulaeto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2017.05.058_b0005","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1086\/587668","article-title":"Severe eczema vaccinatum in a household contact of a smallpox vaccinee","volume":"46","author":"Vora","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2017.05.058_b0010","first-page":"532","article-title":"Progressive vaccinia in a military smallpox vaccinee-United States, 2009","volume":"58","author":"Lederman","year":"2009","journal-title":"Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2017.05.058_b0015","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1093\/infdis\/jis510","article-title":"Progressive vaccinia: case description and laboratory-guided therapy with vaccinia immune globulin, ST-246, and CMX001","volume":"206","author":"Lederman","year":"2012","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2017.05.058_b0020","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1517\/13543784.17.4.555","article-title":"ACAM2000: a newly licensed cell culture-based live vaccinia smallpox vaccine","volume":"17","author":"Greenberg","year":"2008","journal-title":"Expert Opin Invest Drugs"},{"key":"10.1016\/j.vaccine.2017.05.058_b0025","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.ijid.2004.09.002","article-title":"ACAM2000 clonal Vero cell culture vaccinia virus (New York City Board of Health strain) \u2013 a second-generation smallpox vaccine for biological defense","volume":"8","author":"Monath","year":"2004","journal-title":"Int J Inf Dis"},{"key":"10.1016\/j.vaccine.2017.05.058_b0030","doi-asserted-by":"crossref","first-page":"8290","DOI":"10.1016\/j.vaccine.2007.09.050","article-title":"Safety, immunogenicity and protective efficacy in mice of a new cell-cultured Lister smallpox vaccine candidate","volume":"25","author":"Ferrier-Rembert","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.05.058_b0035","first-page":"375","article-title":"The smallpox vaccination strain MVA: marker, genetic structure, experience gained with the parenteral vaccination and behavior in organisms with a debilitated defence mechanism (author's transl)","volume":"167","author":"Mayr","year":"1978","journal-title":"Zentralblatt fur Bakteriologie, Parasitenkunde, Infektionskrankheiten und Hygiene Erste Abteilung Originale Reihe B: Hygiene, Betriebshygiene, praventive Medizin"},{"key":"10.1016\/j.vaccine.2017.05.058_b0040","doi-asserted-by":"crossref","first-page":"e0157335","DOI":"10.1371\/journal.pone.0157335","article-title":"A Randomized, Double-Blind, Placebo-Controlled Phase II Trial Investigating the Safety and Immunogenicity of Modified Vaccinia Ankara Smallpox Vaccine (MVA-BN\u00ae) in 56\u201380-Year-Old Subjects","volume":"11","author":"Greenberg","year":"2016","journal-title":"PloS One"},{"key":"10.1016\/j.vaccine.2017.05.058_b0045","doi-asserted-by":"crossref","first-page":"e0138348","DOI":"10.1371\/journal.pone.0138348","article-title":"A Multicenter, Open-Label, Controlled Phase II Study to Evaluate Safety and Immunogenicity of MVA Smallpox Vaccine (IMVAMUNE) in 18\u201340 Year Old Subjects with Diagnosed Atopic Dermatitis","volume":"10","author":"Greenberg","year":"2015","journal-title":"PloS One"},{"key":"10.1016\/j.vaccine.2017.05.058_b0050","first-page":"269","article-title":"Report of the National Smallpox Vaccination Research Committee: study of side effects, complications and their treatments","volume":"3","author":"Yamaguchi","year":"1975","journal-title":"Clin Virol"},{"key":"10.1016\/j.vaccine.2017.05.058_b0055","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1128\/CVI.00199-14","article-title":"Safety of attenuated smallpox vaccine LC16m8 in immunodeficient mice","volume":"21","author":"Yokote","year":"2014","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2017.05.058_b0060","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1128\/CVI.00782-14","article-title":"Use of the LC16m8 smallpox vaccine in immunocompromised individuals is still too risky","volume":"22","author":"Danon","year":"2015","journal-title":"Clinical and Vaccine Immunology"},{"key":"10.1016\/j.vaccine.2017.05.058_b0065","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1128\/CVI.00055-15","article-title":"Reply to \u201cUse of the LC16m8 smallpox vaccine in immunocompromised individuals is still too risky\u201d","volume":"22","author":"Yokote","year":"2015","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2017.05.058_b0070","doi-asserted-by":"crossref","first-page":"6106","DOI":"10.1016\/j.vaccine.2015.07.111","article-title":"Recent advances in the study of live attenuated cell-cultured smallpox vaccine LC16m8","volume":"33","author":"Eto","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.05.058_b0075","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1086\/513968","article-title":"Immunologic responses to vaccinia vaccines administered by different parenteral routes","volume":"175","author":"McClain","year":"1997","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2017.05.058_b0080","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.virol.2005.06.043","article-title":"The nonreplicating smallpox candidate vaccines defective vaccinia Lister (dVV-L) and modified vaccinia Ankara (MVA) elicit robust long-term protection","volume":"341","author":"Coulibaly","year":"2005","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2017.05.058_b0085","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1038\/nature02331","article-title":"Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox","volume":"428","author":"Earl","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2017.05.058_b0090","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.vaccine.2006.07.022","article-title":"Comparative efficacy of modified vaccinia Ankara (MVA) as a potential replacement smallpox vaccine","volume":"25","author":"Phelps","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.05.058_b0095","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1073\/pnas.262668999","article-title":"Identification of vaccinia virus epitope-specific HLA-A* 0201-restricted T cells and comparative analysis of smallpox vaccines","volume":"100","author":"Drexler","year":"2003","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.vaccine.2017.05.058_b0100","first-page":"283","article-title":"An attenuated strain of vaccinia virus (MVA). Successful intramuscular immunization against vaccinia and variola (author's transl)","volume":"230","author":"Hochstein-Mintzel","year":"1974","journal-title":"Zentralblatt fur Bakteriologie, Parasitenkunde, Infektionskrankheiten und Hygiene Erste Abteilung Originale Reihe A: Medizinische Mikrobiologie und Parasitologie"},{"key":"10.1016\/j.vaccine.2017.05.058_b0105","doi-asserted-by":"crossref","first-page":"4590","DOI":"10.1073\/pnas.0401165101","article-title":"Highly attenuated smallpox vaccine protects mice with and without immune deficiencies against pathogenic vaccinia virus challenge","volume":"101","author":"Wyatt","year":"2004","journal-title":"Proc National Acad Sci USA"},{"key":"10.1016\/j.vaccine.2017.05.058_b0110","doi-asserted-by":"crossref","first-page":"7845","DOI":"10.1128\/JVI.79.12.7845-7851.2005","article-title":"Modified vaccinia virus Ankara protects macaques against respiratory challenge with monkeypox virus","volume":"79","author":"Stittelaar","year":"2005","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2017.05.058_b0115","first-page":"1","article-title":"Clinical guidance for smallpox vaccine use in a postevent vaccination program","volume":"64","author":"Petersen","year":"2015","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.vaccine.2017.05.058_b0120","doi-asserted-by":"crossref","first-page":"3500","DOI":"10.1016\/j.vaccine.2005.02.005","article-title":"Comparative efficacy of replicating smallpox vaccine strains in a murine challenge model","volume":"23","author":"Phelps","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.05.058_b0125","doi-asserted-by":"crossref","first-page":"3358","DOI":"10.1016\/j.vaccine.2004.02.034","article-title":"Differential efficacy of vaccinia virus envelope proteins administered by DNA immunisation in protection of BALB\/c mice from a lethal intranasal poxvirus challenge","volume":"22","author":"Pulford","year":"2004","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.05.058_b0130","series-title":"Smallpox and its eradication","author":"Fenner","year":"1988"},{"key":"10.1016\/j.vaccine.2017.05.058_b0135","doi-asserted-by":"crossref","first-page":"11029","DOI":"10.1073\/pnas.93.20.11029","article-title":"A mechanism for the inhibition of fever by a virus","volume":"93","author":"Alcam\u00ed","year":"1996","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.vaccine.2017.05.058_b0140","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/S0952-7915(00)00109-6","article-title":"Modulation of chemokines by poxvirus infections","volume":"12","author":"Mahalingam","year":"2000","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.vaccine.2017.05.058_b0145","series-title":"Seminars in immunology","first-page":"59","article-title":"Immunology 101 at poxvirus U: immune evasion genes","author":"Moss","year":"2001"},{"key":"10.1016\/j.vaccine.2017.05.058_b0150","doi-asserted-by":"crossref","first-page":"9960","DOI":"10.1128\/JVI.77.18.9960-9968.2003","article-title":"Vaccinia virus interleukin-18-binding protein promotes virulence by reducing gamma interferon production and natural killer and T-cell activity","volume":"77","author":"Reading","year":"2003","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2017.05.058_b0155","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1099\/vir.0.055921-0","article-title":"Vaccinia virus immune evasion: mechanisms, virulence and immunogenicity","volume":"94","author":"Smith","year":"2013","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2017.05.058_b0160","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1099\/vir.0.19285-0","article-title":"A kinetic analysis of immune mediators in the lungs of mice infected with vaccinia virus and comparison with intradermal infection","volume":"84","author":"Reading","year":"2003","journal-title":"J Gen Virol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17307065?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17307065?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:51:09Z","timestamp":1535763069000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X17307065"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7]]},"references-count":32,"journal-issue":{"issue":"31","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["S0264410X17307065"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.05.058","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative Efficacy of Intramuscular and Scarification Routes of Administration of Live Smallpox Vaccine in a Murine Challenge Model","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.05.058","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2017 Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}